Laborecom Therapeutics is a Chicago-based biotech startup developing therapeutics to prevent damage from reperfusion injury. Our lead indication is in reperfusion injury after myocardial infarction.

We are currently supported by a Phase I SBIR from the NHLBI to develop our lead candidate LBRC-101